AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11788220 — intervention group
Group type: COMPARATOR
Intervention: Saline vehicle (control)
Number of subjects: 85
Study 10528036 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b plus prednisolone (200 microg of interferon gamma‐1b given three times per week subcutaneously and 7.5 mg of prednisolone daily)
Number of subjects: 18
Study 10528036 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone (7.5 mg daily, which could be increased to 25 to 50 mg daily)
Number of subjects: 18
Study 10528036 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b plus prednisolone
Number of subjects: 18
Study 10528036 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 18
Study 7730453 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention using selected items of the Brazelton Neonatal Behavioral Assessment Scale
Number of subjects: 60
Study 7730453 — intervention group
Group type: COMPARATOR
Intervention: Talk with a pediatrician about general problems of infant health care
Number of subjects: 60
Study 7730453 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention
Number of subjects: 60
Study 2373132 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol (0.25, 0.50, 1, 2 mg.kg‐1 i.v. and 100 mg oral dose)
Number of subjects: 6
Study 2373132 — intervention group
Group type: COMPARATOR
Intervention: dl-sotalol (1 mg.kg‐1 i.v.)
Number of subjects: 6
Study 38627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 12
Study 38627 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 12
Study 38627 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 12
Study 38627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 12
Study 38627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31571560 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 28
Study 31127932 — intervention group
Group type: EXPERIMENTAL
Intervention: UBE2L3 expression in CeD patients on GFD
Number of subjects: 0
Study 31127932 — intervention group
Group type: COMPARATOR
Intervention: UBE2L3 expression
Number of subjects: 0
Study 28672317 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 721
Study 28672317 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 721
Study 25812529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB) alone
Number of subjects: 101
Study 25812529 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 101
Study 25812529 — intervention group
Group type: COMPARATOR
Intervention: IGB followed by HA at IGB removal (6 months)
Number of subjects: 101
Study 25812529 — intervention group
Group type: COMPARATOR
Intervention: HA and IGB at 6 months
Number of subjects: 101
Study 23688842 — intervention group
Group type: EXPERIMENTAL
Intervention: PES users
Number of subjects: 0
Study 23688842 — intervention group
Group type: COMPARATOR
Intervention: PES non‐users
Number of subjects: 0
Study 21135663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmaceutical interventions (NPIs)
Number of subjects: 10
Study 20032954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (800 mg/day, serum lithium concentration 0.8-1.2 mmol/L)
Number of subjects: 125
Study 20032954 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate sodium (20 mg/kg/day, serum valproate concentration between 70 and 125 µg/ml)
Number of subjects: 125
Study 20032954 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (800 mg/day)
Number of subjects: 125
Study 20032954 — intervention group
Group type: COMPARATOR
Intervention: Valproate sodium (20 mg/kg/day)
Number of subjects: 125
Study 16377775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii LA1 (2 x 10(9) cfu) for six months
Number of subjects: 98
Study 16377775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 16377775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii LA1
Number of subjects: 98
Study 11214780 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.5 mg four times daily for 9 days)
Number of subjects: 10
Study 11214780 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.5 mg four times daily for 9 days) + Warfarin (25 mg single dose on the fourth treatment day)
Number of subjects: 10
Study 11214780 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg single dose)
Number of subjects: 10
Study 11214780 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan alone for 3 days
Number of subjects: 10
Study 11214780 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan + Warfarin
Number of subjects: 10
Study 8894790 — intervention group
Group type: EXPERIMENTAL
Intervention: MgO 3 times a day at a daily dose of 1.0 g (600 mg/day of magnesium)
Number of subjects: 15
Study 2071263 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) nasal spray
Number of subjects: 12
Study 2071263 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6348587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 120 mg daily
Number of subjects: 0
Study 6348587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 240 mg daily
Number of subjects: 0
Study 6348587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30472778 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS (20 Hz)
Number of subjects: 34
Study 30472778 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 34
Study 30472778 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 34
Study 29529475 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 508
Study 29529475 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 508
Study 26767373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 18
Study 26767373 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid load (BAL)
Number of subjects: 18
Study 24789625 — intervention group
Group type: EXPERIMENTAL
Intervention: Massachusetts health reform enacted in 2006
Number of subjects: 208831
Study 21551318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (LA) 60, 90, or 120 mg every 28 days
Number of subjects: 104
Study 21551318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (LA) 120 mg
Number of subjects: 104
Study 20617456 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3‐PSE
Number of subjects: 91
Study 20617456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 91
Study 17548021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting glucose range of 5 to 7 mmol/L
Number of subjects: 20
Study 17548021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting glucose range of 8 to 10 mmol/L
Number of subjects: 20
Study 17548021 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 20
Study 15846111 — intervention group
Group type: EXPERIMENTAL
Intervention: LY293111
Number of subjects: 0
Study 15846111 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 0
Study 12081234 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hMG-hCG method
Number of subjects: 20
Study 12081234 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG step-down method
Number of subjects: 20
Study 12081234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential hMG-GnRH method
Number of subjects: 20
Study 12081234 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hMG-GnRH method
Number of subjects: 20
Study 10443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily, adjusted to 100 mg if necessary)
Number of subjects: 44
Study 10443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release felodipine (5 mg once daily, adjusted to 10 mg if necessary)
Number of subjects: 44
Study 10443063 — intervention group
Group type: COMPARATOR
Intervention: Extended-release felodipine (5 mg once daily)
Number of subjects: 44
Study 8991995 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times daily
Number of subjects: 812
Study 8991995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study 8991995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid 300 mg twice daily
Number of subjects: 812
Study 28244890 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 175
Study 28244890 — intervention group
Group type: EXPERIMENTAL
Intervention: OEP combined with Motivational Interviewing (MI)
Number of subjects: 175
Study 28244890 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 175
Study 28145919 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute rest interval (G-1 min)
Number of subjects: 21
Study 28145919 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute rest interval (G-3 min)
Number of subjects: 21
Study 25887099 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75mg PO BID administered daily until progression or intolerance, one cycle was 28 days.
Number of subjects: 52
Study 22926324 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mL/kg)
Number of subjects: 15
Study 22926324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22926324 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 15
Study 21487148 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d of L-leucine
Number of subjects: 26
Study 21487148 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 26
Study 19653973 — intervention group
Group type: EXPERIMENTAL
Intervention: Novo-venlafaxine XR 75 mg
Number of subjects: 12
Study 19653973 — intervention group
Group type: COMPARATOR
Intervention: Effexor XR 75 mg
Number of subjects: 12
Study 19653973 — intervention group
Group type: EXPERIMENTAL
Intervention: Gen-citalopram 40 mg
Number of subjects: 12
Study 19653973 — intervention group
Group type: COMPARATOR
Intervention: Celexa 40 mg
Number of subjects: 12
Study 17559852 — intervention group
Group type: EXPERIMENTAL
Intervention: High salivary testosterone levels
Number of subjects: 0
Study 17559852 — intervention group
Group type: COMPARATOR
Intervention: Low salivary testosterone levels
Number of subjects: 0
Study 15302319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2)
Number of subjects: 20
Study 15302319 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (antiprostaglandin)
Number of subjects: 20
Study 11598430 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential-existential group psychotherapy (EEGP)
Number of subjects: 0
Study 11598430 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 0
Study 11598430 — intervention group
Group type: EXPERIMENTAL
Intervention: EEGP
Number of subjects: 0
Study 11598430 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 0
Study 9486567 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (two cycles of cisplatin, vincristine, peplomycin, with or without mitomycin C)
Number of subjects: 141
Study 9486567 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 141
Study 9486567 — intervention group
Group type: COMPARATOR
Intervention: Surgery with or without peplomycin chemotherapy (Group A)
Number of subjects: 141
Study 9486567 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy with or without concomitant peplomycin chemotherapy followed by surgery (Group B)
Number of subjects: 141
Study 8018525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral recombinant interferon gamma (rIFN-gamma)
Number of subjects: 31
Study 8018525 — intervention group
Group type: COMPARATOR
Intervention: Control group (subcutaneous reservoir of rIFN-gamma injections)
Number of subjects: 31
Study 2555713 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (up to 100 mg per day)
Number of subjects: 12
Study 818490 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline maleate
Number of subjects: 7
Study 818490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30701368 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay mesh (group A)
Number of subjects: 160
Study 30701368 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal wall closure (no mesh, group B)
Number of subjects: 160
Study 28482639 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese calligraphy writing training (n = 48)
Number of subjects: 99
Study 28482639 — intervention group
Group type: COMPARATOR
Intervention: Control (tablet computer training) (n = 51)
Number of subjects: 99
Study 25203489 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 195
Study 25203489 — intervention group
Group type: COMPARATOR
Intervention: Flexible Ureterorenoscopy (RIRS)
Number of subjects: 195
Study 24012146 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-silymarin mix (240μg selenium plus 570mg silymarin daily for 6 months)
Number of subjects: 55
Study 24012146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 20888671 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free propofol infusion
Number of subjects: 523
Study 20888671 — intervention group
Group type: COMPARATOR
Intervention: No propofol
Number of subjects: 523
Study 18972786 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A1 and B1 (irradiated dentin surface with GIC placed after irradiation)
Number of subjects: 30
Study 18972786 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A2 and B2 (GIC placed on dentin surface before irradiation)
Number of subjects: 30
Study 18972786 — intervention group
Group type: COMPARATOR
Intervention: Groups C1 and C2 (non-irradiated controls)
Number of subjects: 30
Study 16525231 — intervention group
Group type: EXPERIMENTAL
Intervention: Boostrix (reduced‐antigen diphtheria‐tetanus‐acellular pertussis)
Number of subjects: 320
Study 16525231 — intervention group
Group type: COMPARATOR
Intervention: Tetavax (licensed monovalent tetanus‐toxoid vaccine)
Number of subjects: 320
Study 13679719 — intervention group
Group type: EXPERIMENTAL
Intervention: Handipark score
Number of subjects: 30
Study 10634404 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65Ab positive subjects (61/569, 10.7%)
Number of subjects: 569
Study 10634404 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65-CAb in insulin-treated subjects
Number of subjects: 569
Study 10634404 — intervention group
Group type: COMPARATOR
Intervention: GAD65-CAb in subjects treated with hypoglycemic agents and/or diet
Number of subjects: 569
Study 10634404 — intervention group
Group type: COMPARATOR
Intervention: GAD65-MAb in subjects treated with hypoglycemic agents and/or diet
Number of subjects: 569
Study 10634404 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65-CAb
Number of subjects: 569
Study 10634404 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65-M+CAb
Number of subjects: 569
Study 10634404 — intervention group
Group type: COMPARATOR
Intervention: GAD65-MAb only
Number of subjects: 569
Study 9374965 — intervention group
Group type: EXPERIMENTAL
Intervention: Gowning status (gown)
Number of subjects: 895
Study 9374965 — intervention group
Group type: COMPARATOR
Intervention: Non-gown status (no gown)
Number of subjects: 895
Study 9374965 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 895
Study 9374965 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients seeing a doctor for the first time
Number of subjects: 895
Study 1312556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil and low sodium
Number of subjects: 106
Study 1312556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil and low sodium
Number of subjects: 106
Study 1312556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil and normal sodium
Number of subjects: 106
Study 1312556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil and normal sodium
Number of subjects: 106
Study 2858842 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 53
Study 2858842 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 53
Study 2858842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30692018 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyPump (high-repetition low-load group session)
Number of subjects: 92
Study 30692018 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy load resistance training with a personal trainer
Number of subjects: 92
Study 30692018 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-supervised heavy load resistance training
Number of subjects: 92
Study 30692018 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 92
Study 29503112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of MenACWY-TT at month 0 (ACWY_1)
Number of subjects: 802
Study 29503112 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of MenACWY-TT at month 0 and month 2 (ACWY_2)
Number of subjects: 802
Study 29503112 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT and PCV13 co-administered at month 0 (Co-ad)
Number of subjects: 802
Study 29503112 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 at month 0 and MenACWY-TT at month 2 (PCV13/ACWY)
Number of subjects: 802
Study 29503112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 802
Study 26896121 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Outlook Program (7-week online self-management program)
Number of subjects: 132
Study 26896121 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 132
Study 24666176 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosert(®)
Number of subjects: 280
Study 24666176 — intervention group
Group type: COMPARATOR
Intervention: Mirena(®)
Number of subjects: 280
Study 22571245 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive talking intervention (EE)
Number of subjects: 58
Study 22571245 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study 20478097 — intervention group
Group type: EXPERIMENTAL
Intervention: RUD-FOCA (Resource Utilization in Dementia - Formal Care)
Number of subjects: 148
Study 17476596 — intervention group
Group type: EXPERIMENTAL
Intervention: IV remifentanil (group B)
Number of subjects: 116
Study 17476596 — intervention group
Group type: COMPARATOR
Intervention: IV midazolam and pethidine (group A)
Number of subjects: 116
Study 15188106 — intervention group
Group type: EXPERIMENTAL
Intervention: Zwey‐Muller cementless total hip arthroplasty (THA)
Number of subjects: 80
Study 15188106 — intervention group
Group type: EXPERIMENTAL
Intervention: Corail cementless total hip arthroplasty (THA)
Number of subjects: 80
Study 15188106 — intervention group
Group type: EXPERIMENTAL
Intervention: Optifix cementless total hip arthroplasty (THA)
Number of subjects: 80
Study 15188106 — intervention group
Group type: EXPERIMENTAL
Intervention: Autophor 900S cementless total hip arthroplasty (THA)
Number of subjects: 80
Study 12218423 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.02 to 0.06 mg/kg per day)
Number of subjects: 110
Study 12218423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 12218423 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110
Study 9832297 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (two 0.5-g tablets)
Number of subjects: 28
Study 8076441 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% sodium fusidate ointment applied in the anterior nares and in the pericatheter skin twice daily for 5 days
Number of subjects: 31
Study 8076441 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 200 mg taken every 48 hours for 5 days
Number of subjects: 31
Study 8076441 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 2518898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum and group sessions (n = 37)
Number of subjects: 106
Study 2518898 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with identical intervention (n = 38)
Number of subjects: 106
Study 2518898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum with follow-up in the consulting room (n = 31)
Number of subjects: 106
Study 1195474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfacytine 1 gm daily for 10 days
Number of subjects: 98
Study 1195474 — intervention group
Group type: COMPARATOR
Intervention: Sulfisoxazole 4 gm daily for 10 days
Number of subjects: 98
Study 31444776 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended pouch RYGB (EP-GB)
Number of subjects: 132
Study 31444776 — intervention group
Group type: COMPARATOR
Intervention: Standard pouch RYGB (S-GB)
Number of subjects: 132
Study 31274193 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic contour validation using a decision tree model based on texture features from the core subregion.
Number of subjects: 55
Study 31274193 — intervention group
Group type: COMPARATOR
Intervention: Ground-truth contours for comparison.
Number of subjects: 55
Study 29857884 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiatsu + physical activity
Number of subjects: 0
Study 29857884 — intervention group
Group type: COMPARATOR
Intervention: Physical activity alone
Number of subjects: 0
Study 27149410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 112
Study 27149410 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema therapy
Number of subjects: 112
Study 27149410 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite-focused cognitive-behavioural therapy
Number of subjects: 112
Study 24556773 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive department/division culture
Number of subjects: 133